



World Health  
Organization

# WHO COVID-19 vaccines research

What recent evidence do we have that omicron is evading immunity and what are the implications?

14 February 2022

13:00 – 17:15 Central European Time CET

**DRAFT** Agenda



**R&D**Blueprint

Powering research  
to prevent epidemics

## Objectives

In continuation to the scientific discussions on COVID-19 vaccines research, WHO R&D Blueprint is organizing a consultation to review emerging data related to the omicron variant. During this forthcoming consultation global experts will review the available evidence, critically appraise the data, and outline research priorities.

DRAFT

**Chairperson: William Dowling**

Time	Topic	Speakers
13:00 – 13:05	Welcome and Objectives of the meeting	William Dowling
<b>Session 1. Immunological studies</b>		
13:05 – 13:15	Overview of published neutralization data	Ioannis Sitaras (JHU-IVAC)
13:15 – 14:55	Research presentations	Alex Sigal (African Health Research Institute, South Africa) Seshadri Vasan (CSIRO, Australia) Florian Krammer (Icahn School of Medicine at Mount Sinai, US) George Gao (Chinese Center for Disease Control and Protection) Janine Kimpel (Medical University of Innsbruck, Austria) Gili Regev-Yochay (Sheba Medical Center, Israel) Malik Peiris (Hong Kong University) <b>TBC</b> Galit Alter (Harvard, US) Wendy Burgers (University of Cape Town, South Africa) Alba Grifoni (La Jolla Institute, US) Martin Michaelis (University of Kent, UK)
14:55 – 15:00	<b>BREAK</b>	
<b>Session 2. Animal studies</b>		
15:00 – 16:30	Research presentations	Kanta Subbarao (Doherty Institute, Australia) Jasper Chan (Hong Kong University) Yper Hall (UK Health Security Agency) Larissa Thackray (Washington University, US) David Hawman (National Institute of Allergy and Infectious Diseases (NIAID), US) Dan Barouch (Harvard, US) James Stewart (Univ of Liverpool, UK) Vincent Munster (NIAID, US) Bob Seder (NIAID Vaccine Research Center, US)
<b>Session 3.</b>		
16:30 – 17:05	<u>Panel discussion: Interpretation and Next Steps</u> - What do the immunological and animal data tell us about the potential utility of an omicron specific vaccine? - Discuss the strengths and weaknesses of the animal models to assess vaccines - What other studies are still needed?	Moderator: Phil Krause  Barney Graham Linfa Wang (Duke-NUS, Singapore) Sergio Nishioka Narendra Arora (Inclen Trust, India) Elizabeth Miller (London School of Hygiene & Tropical Medicine) Adolfo Garcia-Sastre (Icahn School of Medicine at Mount Sinai, US) Nancy Sullivan (NIAID Vaccine Research Center, US)
17:05 - 17:15	Overall conclusions, knowledge gaps and research priorities	William Dowling
	<b>END OF MEETING</b>	